Candid Villanueva
Overview
Explore the profile of Candid Villanueva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villanueva C, Tripathi D, Bosch J
Nat Rev Gastroenterol Hepatol
. 2025 Jan;
PMID: 39870944
Two main stages are differentiated in patients with advanced chronic liver disease (ACLD), one compensated (cACLD) with an excellent prognosis, and the other decompensated (dACLD), defined by the appearance of...
2.
Sanchez-Aldehuelo R, Villanueva C, Genesca J, Garcia-Pagan J, Castillo E, Calleja J, et al.
JHEP Rep
. 2025 Jan;
7(2):101231.
PMID: 39850960
Background & Aims: Systemic inflammation is a driver of decompensation in cirrhosis with unclear relevance in the compensated stage. We evaluated inflammation and bacterial translocation markers in compensated cirrhosis and...
3.
Fortea J, Alvarado-Tapias E, Simbrunner B, Ezcurra I, Hernandez-Gea V, Aracil C, et al.
J Hepatol
. 2024 Dec;
PMID: 39701300
Background & Aims: Data on the effectiveness of classical non-selective beta-blockers (cNSBBs, i.e., propranolol and nadolol) vs. carvedilol in patients with cirrhosis are scarce. In the present study, we aimed...
4.
Perez-Campuzano V, Rautou P, Marjot T, Praktiknjo M, Alvarado-Tapias E, Turco L, et al.
JHEP Rep
. 2024 Nov;
6(12):101191.
PMID: 39583091
Background & Aims: Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients...
5.
Alvarado-Tapias E, Brujats A, Puente A, Ardevol A, Rodriguez-Arias A, Fajardo J, et al.
Hepatology
. 2024 Nov;
PMID: 39509369
Background And Aims: Carvedilol is a nonselective β-blocker (NSBB) with anti-α1-adrenergic activity, more effective than traditional NSBBs in reducing portal pressure hepatic venous pressure gradient (HVPG). However, 35%-45% of patients...
6.
Dajti E, Villanueva C, Berzigotti A, Brujats A, Albillos A, Genesca J, et al.
J Hepatol
. 2024 Sep;
82(3):490-498.
PMID: 39303875
Background & Aims: Whether non-invasive tests (NITs) can accurately select patients with cirrhosis requiring non-selective beta-blockers (NSBBs) for clinically significant portal hypertension (CSPH) and prevention of decompensation is unclear. Our...
7.
Magaz M, Giudicelli-Lett H, Abraldes J, Nicoara-Farcau O, Turon F, Rajoriya N, et al.
J Hepatol
. 2024 Aug;
82(1):72-83.
PMID: 39181213
Background & Aims: Current knowledge of the natural history of patients with porto-sinusoidal vascular disorder (PSVD) is derived from small studies. The aim of the present study was to determine...
8.
Brujats A, Huerta A, Osuna-Gomez R, Guinart-Cuadra A, Ferrero-Gregori A, Pujol C, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125872
Advanced chronic liver disease (ACLD) is associated with a wide spectrum of immune dysfunction. The clinical impact of SARS-CoV-2 on the development of decompensation and immune response in unvaccinated outpatients...
9.
Paternostro R, Kwanten W, Hofer B, Semmler G, Bagdadi A, Luzko I, et al.
J Hepatol
. 2024 Jun;
81(5):827-836.
PMID: 38823501
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of advanced chronic liver disease (ACLD). Portal hypertension drives hepatic decompensation and is best diagnosed by hepatic...
10.
Garcia-Guix M, Ardevol A, Sapena V, Alvarado-Tapias E, Huertas A, Brujats A, et al.
Liver Int
. 2024 Apr;
44(8):1971-1989.
PMID: 38634685
Background And Aims: Decompensated-cirrhosis encompasses several stages with different prognosis, such as bleeding, ascites and bleeding-plus-ascites. Development of further-decompensation worsens survival, while non-selective β-blockers (NSBBs) can modify the risk. However,...